Trial Profile
Bevacizumab monotherapy as salvage therapy for patients with advanced clear cell renal cell carcinoma pretreated with targeted drugs
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Aug 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Aug 2015 New trial record